Last edition
News about Global Pharma
FDA Accepts IND for Affinia's AFTX-201 Gene Therapy in BAG3 Dilated Cardiomyopathy
Affinia Therapeutics receives FDA clearance to begin clinical testing of AFTX-201, a next-generation AAV gene therapy for BAG3-associated dilated cardiomyopathy, with Phase 1/2 UPBEAT trial set to begin in 2026.
Global Pharma | 09/02/2026 | By News Bureau
Health Canada Authorises Livmarli Tablet for Cholestatic Pruritus in Alagille Syndrome
Mirum Pharmaceuticals receives Health Canada approval for Livmarli tablet formulation, expanding dosing options for eligible Alagille syndrome patients with cholestatic pruritus.
Global Pharma | 07/02/2026 | By News Bureau
Pfizer Launches Cost Savings Programme on TrumpRx
Pfizer has rolled out a new cost-savings initiative, TrumpRx, aimed at making medicines more affordable for US patients. The programme covers over 30 brands across major therapy areas and reinforces the company’s commitment to lowering drug prices under its landmark agreement with the Trump administration.
Global Pharma | 07/02/2026 | By News Bureau
Lupin Launches Topiramate Extended-Release Capsules in US Following FDA Approval
Lupin rolls out FDA-approved generic topiramate extended-release capsules in the US for epilepsy and migraine treatment.
Global Pharma | 05/02/2026 | By News Bureau
Slingshot Biosciences to Expand into UK and EU Markets
Slingshot Biosciences is expanding its operations into the United Kingdom and European Union to scale deployment of its precision-engineered synthetic cell mimic technology and accelerate cell and gene therapy as well as broader pharmaceutical development.
Global Pharma | 05/02/2026 | By News Bureau
Patent Expiry Headwinds to Drive Novartis Operating Profit Down in 2026
Swiss pharmaceutical major Novartis has forecast a modest decline in operating profit for 2026, marking its first annual drop in a decade amid the looming impact of key drug patent expiries.
Global Pharma | 05/02/2026 | By Darshana | 127
Avidity Biosciences Sets Record Date for Atrium Therapeutics Spin Off Ahead of Novartis Merger
Avidity Biosciences announces February 12, 2026 as the record date for distributing Atrium Therapeutics shares to stockholders as part of its planned Novartis acquisition and cardiology spin-off.
Global Pharma | 03/02/2026 | By News Bureau | 279
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
Global Pharma | 03/02/2026 | By News Bureau | 111
Trace Biosciences Secures FDA IND Clearance for First Nerve-Specific Fluorescent Imaging Agent
FDA clears IND application for LGW16-03, enabling Trace Biosciences to begin first-in-human trials of its nerve-targeted imaging agent designed to reduce accidental nerve injuries during surgery.
Global Pharma | 02/02/2026 | By News Bureau | 100
Illumina has completed its USD 350 million acquisition of SomaLogic, strengthening its multiomics portfolio and expanding large-scale proteomics capabilities to accelerate drug discovery and improve patient outcomes.
Global Pharma | 02/02/2026 | By News Bureau | 217
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy